The present invention provide for methods of inducing an oncolytic effect on tumor cells using Zika virus. The invention also provides for inducing an oncolytic effect on brain tumors and treating brain tumors, and in particular, glioblastomas and neuroblastoma. The treatment involves the administration of Zika virus, which has an oncolytic effect on the tumor cells.

The present invention provides compositions of CD 180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.

The present invention provides compositions of CD180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.

A kit is disclosed, for the destruction of cancer cells with stem cell properties based on the oncolytic action of the Zika virus, associated with the aggressiveness of malignant tumors and an unfavorable clinical prognosis, especially in malignant tumors of the nervous system. The kit contains a pharmaceutical composition, sterile glass vials with a rubber seal, and syringes with sterile and disposable needles for injection.

Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.

CD24-positive malignant and benign tumors are treated by administration of a naturally occurring or modified oncolytic Zika virus. Diseases associated with abnormal T cell activation or T cell-mediated autoimmunity, wherein CD24 expression is increased, are also expected to be treated by administration of a naturally occurring or modified oncolytic Zika virus. Also contemplated are compounds and methods for treating and/or preventing Zika virus infection in a subject.

Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.

Described herein are compositions and methods for treating a disease, particularly a cancer, with a Dengue Virus and, optionally, primed dendritic cells recognizing a tumor antigen. Lysis protocols are described where the lysis does not result in complete or less than complete lysis of cells in order to provide cell surface molecules maintained in a cell surface-embedded state. Non-lethal Dengue virus strains are also provided for therapeutic purposes.

The present invention provides compositions of CD180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.

The invention provides a recombinant West Nile virus, in which the amino acid sequence of envelope E protein is genetically modified to attenuation, and its RNA genome is inserted with a foreign gene fragment. The engineered E gene contains the mutation of five amino acids for reducing its neural virulence to the central nervous system; the integrated foreign gene between E and S1 gene makes a new chimerical virus. Thus, the present invention provides the application of this attenuated West Nile virus as a vaccine in preventive medicine and the application of the RNA-viral vector as a novel gene-drug in the pharmaceutical industry. The newly attenuated virus may fill the gap of no live-attenuated vaccine to the West Nile virus epidemic. The attenuated and recombinant virus can be used as an RNA oncolytic virus to target solid tumors, especially neural tumors, for cancer therapy with higher safety.